03/29/2024 | Press release | Distributed by Public on 03/29/2024 09:01
☒
|
ANNUAL REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
68-0454536
|
(State or other jurisdiction of incorporation or
organization)
|
(I.R.S. Employer Identification No.)
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange On Which Registered
|
Common Stock, par value $0.01 per share
|
NBY
|
NYSE American
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Emerging growth company
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
Auditor firm ID | Auditor Name | Auditor Location |
PCAOB ID No. 100 | WithumSmith+Brown, PC | San Francisco, California |
ITEM15.
|
EXHIBITS, FINANCIAL STATEMENT SCHEDULES
|
Incorporation by Reference
|
Filed
Herewith
|
|||||
Exhibit
Number
|
Exhibit Description
|
Form
|
File
Number
|
Exhibit/
Form 8-K
Item
Reference
|
Filing
Date
|
|
2.1
|
8-K
|
001-3678
|
2.1
|
9/28/2021
|
||
2.2
|
8-K
|
001-3678
|
2.1
|
03/14/2024
|
||
3.1
|
10-K
|
001-33678
|
3.1
|
3/21/2018
|
||
3.2
|
8-K
|
001-33678
|
3.1
|
6/04/2018
|
||
3.3
|
8-K
|
001-33678
|
3.1
|
5/28/2020
|
||
3.4
|
8-K
|
001-33678
|
3.1
|
5/24/2021
|
||
3.5
|
8-K
|
001-33678
|
3.1
|
2/1/2022
|
||
3.6
|
8-K
|
001-33678
|
3.1
|
11/18/2022
|
||
3.7
|
8-K
|
001-33678
|
3.1
|
11/1/2021
|
||
3.8
|
8-K
|
001-33678
|
3.2
|
11/18/2022
|
||
3.9
|
10-K
|
001-33678
|
3.7
|
6/14/2023
|
||
4.1
|
10-K
|
001-33678
|
4.1
|
3/31/2023
|
||
4.2
|
8-K
|
001-33678
|
4.1
|
5/18/2020
|
||
4.3
|
8-K
|
001-33678
|
4.1
|
7/21/2020
|
||
4.4
|
8-K
|
001-33678
|
4.1
|
9/13/2022
|
||
4.5
|
8-K
|
001-33678
|
4.2
|
9/13/2022
|
||
4.6
|
8-K
|
001-33678
|
4.3
|
9/13/2022
|
||
4.7
|
8-K
|
001-33678
|
4.4
|
9/13/2022
|
||
4.8
|
8-K
|
001-33678
|
4.5
|
9/13/2022
|
||
4.9
|
8-K
|
001-33678
|
4.6
|
9/13/2022
|
||
4.10
|
8-K
|
001-33678
|
4.1
|
4/27/2023
|
||
4.11
|
8-K
|
001-33678
|
4.2
|
4/27/2023
|
4.12
|
8-K
|
001-33678
|
4.3
|
4/27/2023
|
||
4.13
|
8-K
|
001-33678
|
4.4
|
4/27/2023
|
||
4.14
|
8-K
|
001-33678
|
4.1
|
12/21/2023
|
||
4.15
|
8-K
|
001-33678
|
4.2
|
3/25/2024
|
||
4.16
|
8-K
|
001-33678
|
4.3
|
3/25/2024
|
||
10.1
|
10-K
|
001-33678
|
10.1
|
3/29/2022
|
||
10.2+
|
S-8
|
333-215680
|
99.1
|
1/24/2017
|
||
10.3+
|
S-8
|
333-218469
|
99.1
|
6/02/2017
|
||
10.4+
|
S-8
|
333-218469
|
99.2
|
6/02/2017
|
||
10.5+
|
8-K
|
001-33678
|
10.1
|
2/6/2020
|
||
10.6+
|
8-K
|
001-33678
|
10.6
|
1/28/2022
|
||
10.7+
|
8-K
|
001-33678
|
10.3
|
12/11/2023
|
||
10.8+
|
10-K
|
001-33678
|
10.8
|
3/26/2024
|
||
10.9
|
8-K
|
001-33678
|
10.1
|
8/26/2016
|
||
10.10
|
8-K
|
001-33678
|
10.2
|
1/28/2022
|
||
10.11†
|
10-K
|
001-33678
|
10.18
|
3/27/2012
|
||
10.12
|
8-K
|
001-33678
|
1.1
|
5/14/2021
|
||
10.13
|
8-K
|
001-33678
|
10.1
|
7/21/2020
|
||
10.14
|
8-K
|
001-33678
|
10.2
|
7/21/2020
|
||
10.15
|
8-K
|
001-33678
|
10.3
|
7/21/2020
|
||
10.16
|
8-K
|
001-33678
|
1.1
|
11/01/2021
|
||
10.17
|
8-K
|
001-33678
|
10.1
|
11/01/2021
|
||
10.18
|
8-K
|
001-33678
|
10.1
|
9/13/2022
|
||
10.19
|
8-K
|
001-33678
|
10.2
|
9/13/2022
|
||
10.20
|
8-K
|
001-33678
|
10.3
|
9/13/2022
|
||
10.21
|
8-K
|
001-33678
|
10.4
|
9/13/2022
|
||
10.22+
|
8-K
|
001-33678
|
10.8
|
3/31/2023
|
||
10.23
|
8-K
|
001-33678
|
10.1
|
12/21/2023
|
||
10.24*
|
8-K
|
001-33678
|
10.1
|
1/05/2024
|
||
10.25
|
8-K
|
001-33678
|
10.1
|
4/27/2023
|
||
10.26*
|
8-K
|
001-33678
|
10.2
|
4/27/2023
|
||
10.27*
|
8-K
|
001-33678
|
10.3
|
3/25/2024
|
||
10.28
|
8-K
|
001-33678
|
10.3
|
4/27/2023
|
||
10.29*
|
8-K
|
001-33678
|
10.4
|
3/25/2024
|
10.30
|
8-K
|
001-33678
|
10.4
|
4/27/2023
|
||
10.31
|
8-K
|
001-33678
|
10.5
|
4/27/2023
|
||
21
|
10-K
|
001-33678
|
21
|
3/26/2024
|
||
23.1
|
10-K
|
001-33678
|
23.1
|
3/26/2024
|
||
31.1
|
Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)
|
X
|
||||
31.2
|
Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)
|
X
|
||||
32.1
|
Certification by the Chief Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350)
|
X
|
||||
32.2
|
Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350)
|
X
|
||||
97
|
10-K
|
001-33678
|
97
|
3/26/2024
|
||
101.INS
|
Inline XBRL Instance Document
|
X
|
||||
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document
|
X
|
||||
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
X
|
||||
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase
|
X
|
||||
101.LAB
|
Inline XBRL Taxonomy Extension Labels Linkbase Document
|
X
|
||||
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
X
|
||||
104
|
The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments)
|
X
|
+
|
Indicates a management contract or compensatory plan or arrangement
|
†
|
NovaBay Pharmaceuticals, Inc. has been granted confidential treatment with respect to certain portions of this exhibit (indicated by asterisks), which have been separately filed with the Securities and Exchange Commission.
|
*
|
Certain confidential portions of this exhibit were omitted by means of marking such portions with brackets because the confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
|
Date: March 29, 2024
|
||
By:
|
/s/ Justin Hall
|
|
Justin Hall
Chief Executive Officer, General Counsel and Director
(principal executive officer)
|